International Stem Cell Corp. (ISCO) Posts Q1 Business Highlights, Financial Results
International Stem Cell Corp., a California-based biotech company developing novel stem cell-based therapies and biomedical products, today issued a business update and posted its financial results for the first quarter of 2015. Business updates for the first quarter of the year include: • Completed the required preclinical studies and submitted a clinical trial exemption application to the Australian Therapeutics Goods Administration (TGA) to begin the phase 1/2a clinical study of the company's cell therapy for the treatment of Parkinson's disease. To be administered through the company’s wholly owned Australian subsidiary, Cyto Therapeutics Pty Ltd. • Completed the manufacture of the…